Characterization of the expression of the pro-metastatic
MenaINV isoform during breast tumor progression
The MIT Faculty has made this article openly available.
Please share
how this access benefits you. Your story matters.
Citation
Oudin, Madeleine J. et al. “Characterization of the Expression of the
pro-Metastatic MenaINV Isoform during Breast Tumor Progression.”
Clinical & Experimental Metastasis 33.3 (2016): 249–261.
As Published
http://dx.doi.org/10.1007/s10585-015-9775-5
Publisher
Springer Netherlands
Version
Author's final manuscript
Citable link
http://hdl.handle.net/1721.1/103617
Terms of Use
Creative Commons Attribution-Noncommercial-Share Alike
Detailed Terms
http://creativecommons.org/licenses/by-nc-sa/4.0/
Article type: Original article
Characterization of the expression of the pro-metastatic MenaINV isoform during breast tumor progression
Madeleine J. Oudin1# *, Shannon K. Hughes1,2#, Nazanin Rohani1, Mira N. Moufarrej2, Joan G. Jones5, John S. Condeelis3, Douglas A. Lauffenburger 1,2, Frank B. Gertler1,4
#These authors contributed equally.
1
Koch Institute for Integrative Cancer Research, MIT, Cambridge, MA 02139, USA 2
Department of Biological Engineering, MIT, Cambridge, MA 02139, USA 3
Department of Anatomy and Structural Biology, Albert Einstein College of Medicine, Bronx, NY, 10461, USA
4
Department of Biology, MIT, Cambridge, MA 02139, US 5
Integrated Imaging Program, Albert Einstein College of Medicine, Bronx, NY, 10461, USA
*for correspondence: Madeleine J. Oudin
Koch Institute for Integrative Cancer Research M.I.T., 76-317 77 Massachusetts Ave Cambridge, MA 02139 Ph: 617-258-5996 Email: mjoudin@mit.edu Acknowledgements:
This work was supported by Department of Defense Breast Cancer Research Program grants W81XWH-10-1-0040 to SKH and W81XWH-13-1-0031 to MJO, NIH grant U54-CA112967 to FBG and DAL and GM58801 to FBG, funds from the Ludwig Center at MIT to FBG and NR, the KI NCI Core Grant P30-CA14051, and CA150344 to JC and CA100324 for JJ. JJ, JC and FG are compensated members if the scientific advisory board of MetaStat. No funding was provided by MetaStat for this work. We thank the Histology facilities in the KI Swanson Biotechnology Center for support. We thank Evanthia Roussos for gifts of tumor tissue.
Abbreviations:
DCIS Ductal Carcinoma In Situ EGF Epidermal Growth Factor
EMT Epithelial to Mesenchymal Transition FFPE Formalin Fixed Paraffin Embedded GFP Green Fluorescent Protein
IP Immunoprecipitation LN Lymph node
SMA Smooth Muscle Actin
Abstract
Several functionally distinct isoforms of the actin regulatory Mena are produced by alternative splicing during tumor progression. Forced expression of the MenaINV isoform drives invasion, intravasation and metastasis. However, the abundance and distribution of endogenously expressed MenaINV within primary tumors during progression remain unknown, as most studies to date have only assessed relative mRNA levels from dissociated tumor samples. We have developed a MenaINV isoform-specific monoclonal
antibody and used it to examine MenaINV expression patterns in mouse mammary and human breast tumors. MenaINV expression increases during tumor progression and to examine the relationship between MenaINV expression and markers for epithelial or mesenchymal status, stemness, stromal cell types and hypoxic regions. Further, while MenaINV robustly expressed in vascularized areas of the tumor, it is not confined to cells adjacent to blood vessels. Altogether, these data demonstrate the specificity and utility of the anti-MenaINV-isoform specific antibody, and provide the first description of endogenous MenaINV protein expression in mouse and human tumors.
4-6 keywords
Introduction
While metastasis remains the leading cause of death in cancer patients, the molecular mechanisms driving this process are incompletely understood. Changes within the primary tumor itself or in the
microenvironment can lead to local invasion and ultimately metastasis. For example, during the epithelial to mesenchymal transition (EMT), cells can undergo changes in gene expression which endow carcinoma cells with aggressive, metastatic characteristics [1]. Increased matrix stiffening, collagen crosslinking and integrin-dependent focal adhesion are also associated with breast tumorigenesis and can promote
progression to an invasive and metastatic phenotype [2], [3]. Hypoxia, via stabilization of hypoxia-inducible factor (HIF1α), regulates the expression of multiple genes that can lead to changes in anaerobic metabolism, angiogenesis, invasion and survival [4]. Finally, the tumor stroma plays an important role in promoting metastasis as recruitment of macrophages or bone marrow derived cells to the primary tumor site can increase cell migration, invasion and intravasation [5].
Mena, a member of the Ena/VASP family, is a known regulator of actin polymerization and cell:matrix, and cell: adhesion that is upregulated in various human epithelial tumors, including breast, pancreas, lung, colon and cervix [6]. In the MMTV-PyMT genetic model of breast cancer, genetic ablation of Mena significantly reduces in vivo tumor cell motility, intravasation and metastasis without altering mammary tumor burden, growth or histologic progression to carcinoma [7]. Mena-expressing cells are components of TMEM (tumor microenvironment of metastasis), tripartite structures comprised of a Mena-expressing tumor cell, an endothelial cell and a macrophage all contacting each other. TMEMs are sites of
intravasation in mouse mammary tumors [8], and TMEM density correlates with risk of distant metastasis in ER-/HER2+ breast cancer patients [9], [10].
During tumor progression, Mena is alternatively spliced to produce multiple isoforms that can affect tumor cell phenotypes in different ways [6]. Expression of Mena11a, an isoform of Mena that contains an additional 21 amino acids in the EVH2 domain of Mena, is highly expressed in primary tumor cells, but downregulated in invasive cells [11], and has been shown to decrease motility in vivo and dampen invasion responses to EGF [12]. In two patient cohorts, quantitative immunofluorescence of a biomarker Menacalc derived from the difference in expression levels of all Mena isoforms (“panMena”) and Mena11a showed that high Menacalc levels are associated with poor disease-specific survival[13], [14].
Conversely, inclusion of the 19-amino acid sequence encoded by the ‘INV’ exon (Fig1A) in Mena
promotes invasion, intravasation and metastasis by sensitizing cells to EGF, subsequently allowing them to invade in response to low concentrations of growth factor [12], [15]. Notably, the lack of a sensitive isoform-specific antibody capable of detecting MenaINV in tumors has necessitated use of RT-PCR analysis of mRNA isolated from dissociated tumor tissues as a proxy for the protein. Using xenograft and
spontaneous breast tumor models, we found that expression of MenaINV mRNA is comparatively high in invasive cells collected by EGF chemotaxis from the primary tumor [11]. Furthermore, in cells isolated from fine needle aspirates (FNA) of breast human tumors, MenaINV mRNA levels were relatively higher in the subset of tumor cells that had traversed a human endothelial cell monolayer in in vitro intravasation assays [16]. Finally, in human breast cancer patients, relative levels MenaINV mRNA in FNA biopsies from freshly resected breast tumor samples were observed to correlate with the number of TMEM sites found histological sections from the matched tumor tissue [16], [17]. However, the abundance and distribution of MenaINV protein within primary tumors have not yet been determined. Given the relatively high expression of MenaINV in invasive tumor cell subpopulations, and the ability of MenaINV expression to enhance microenvironment-dependent metastatic phenotypes, reagents that allow for analysis of MenaINV protein levels and distribution within histological sections of patient tumors might be used to gain insight into the biology of tumor progression and, potentially, as a prognostic biomarker.
Using a newly generated isoform-specific antibody validated in three assays, we show that MenaINV protein expression increases during tumorigenesis and progression and is correlated with blood vessel density. Furthermore, we show that while MenaINV expression is inversely correlated with E-cadherin, it is not restricted to mesenchymal-like cells, is not detected in stromal cells, and does not correlate with increased proliferation, stemness, macrophage density, or hypoxia. These results provide insight into the
to describe its pro-metastatic effects, and provide the basis for evaluating MenaINV as potential biomarker for clinical use.
Results
Validation of the MenaINV antibody for use in Western Blot, ELISA and immuhistochemistry
To analyze MenaINV protein expression and distribution, we developed an isoform-specific monoclonal antibody that selectively recognizes the 19aa sequence (identical in human and mouse) encoded by the INV exon (“anti-INV”) [18] (Fig 1A). Anti-INV recognized GFP-MenaINV - but not GFP-Mena or GFP alone - in western blots of lysates of MDA-MB231 cells that express the corresponding constructs. Anti-panMena, which recognizes all known Mena isoforms [19], detected ectopic GFP-Mena, GFP-MenaINV and
endogenous Mena (Fig 1B). We developed an ELISA assay to detect and to quantify MenaINV levels in protein lysates. We confirmed the specificity of the ELISA assay using two peptides expressing either EVH1-LERER or EVH1-INV-LERER. Increasing the concentration of the EVH1-INV-LERER peptide correlated with an increase in signal as detected by the ELISA assay, while no signal was detected with the EVH1-LERER peptide (Fig 1C). We then measured MenaINV expression in lysates collected from MVD7 fibroblasts, which lack all three Ena/VASP proteins [20], MDA-MB-231 cells expressing ectopic GFP-Mena (“231-GFP-Mena”) or GFP-GFP-MenaINV (“231-MenaINV”). Using the ELISA assay, no signal above the assay detection limit for MenaINV was detected in MVD7 fibroblasts, or 231-Mena cells; while a strong signal was detected in 231-MenaINV cells (Fig 1D). Together, these data confirmed the specificity of the antibody and quantitative nature of the ELISA assay.
Given that we have shown that at the mRNA level, MenaINV expression is enriched in invasive cell populations of xenograft tumors, PyMT tumors [21], and in FNA biopsies of human breast tumors[16], we were interested in visualizing the distribution of MenaINV protein within tumors. The MenaINV antibody was validated for use and specificity in staining of formalin-fixed paraffin embedded (FFPE) tumor sections by comparing anti-INV signals in xenografts of cells expressing GFP-MenaINV or GFP-Mena (Fig 1E). As expected, strong signal for MenaINV was observed in GFP-MenaINV xenograft tissue sections, but absent in GFP-Mena tumor sections. Secondly, we examined mammary carcinomas arising from transgenic MMTV-PyMT expression and found that MenaINV was heterogeneously distributed in this model.
Furthermore, as expected we did not detect specific MenaINV signal in tissue sections of tumors isolated from Mena knockout mice carrying the MMTV-PyMT transgene, used here as a negative control (Fig 1F). These data confirm the specificity and utility of the antibody for use in immunodetection of MenaINV in FFPE tissue sections.
MenaINV expression in tumors is heterogeneous, but increases during progression in mouse and human samples
Next, we examined Mena and MenaINV staining in normal mammary gland fat pad tissue and in advanced MMTV-PyMT tumors by immunofluorescence of FFPE sections (Fig 2A, B). While Mena is widely expressed in ducts, we found low, heterogeneous staining for MenaINV in normal ductal structures within the mammary gland, with significantly stronger MenaINV staining intensity in tumor tissue (Fig 2C). We then asked if MenaINV is expressed in cells within non-invasive tumor structures with intact basement membranes, marked by staining with Laminin, and found that MenaINV detectable in encapsulated pre-invasive tumor structures.
We then studied the relationship between Mena and MenaINV expression during tumor progression in the MMTV-PyMT model [22]. Overall, we observed heterogeneous MenaINV staining in subsets of Mena-expressing cells in MMTV-PyMT tumors (Fig 2E). Specifically, there were significant increases in both Mena and MenaINV staining in both adenoma and carcinoma tumor regions relative to hyperplasia (Fig 2F,G). Together, these data suggest that in the MMTV-PyMT model Mena and MenaINV expression increases during progression from hyperplasia to adenoma, with no further increases during progression to carcinoma.
Next, we examined Mena and MenaINV protein expression and localization in a small cohort of both metastatic and non-metastatic human breast tumors (tumor characteristics described in Fig S1). We found that while Mena is expressed at high levels in ductal structures in non-metastatic tumors (Fig 3A-C) only low levels of MenaINV were detected. As shown in the PyMT mouse model, we found robust levels of MenaINV in structures characterized as ductal carcinoma in situ (DCIS), which are known to contain an intact basement membrane (Fig 3D-F), with both isoforms expressed in these tissues. Finally, relatively higher levels of MenaINV were observed in metastatic patients. Patients with metastatic disease showed increased percentage of cells expressing MenaINV (Fig 3J), as well as increased levels of MenaINV, as detected by quantitative immunofluorescence (Fig 3L). Levels of Mena were not significantly different between non-metastatic and metastatic cases (Fig 3K). Overall, these data demonstrate that MenaINV expression increases during tumor progression in both mouse and human tumors.
MenaINV is not expressed in macrophages, endothelial cells or fibroblasts
The tumor microenvironment is composed of a variety of tumor and stromal cells, which can also
contribute to tumor progression [5]. We were interested in investigating whether MenaINV was expressed in endothelial cells, macrophages and fibroblasts within tumors. We used established markers to stain for all three subpopulations in PyMT tumors: Iba1 for macrophages (Fig 4A); αSMA (smooth muscle actin) for fibroblasts (Fig 4B); CD31 for endothelial cells (Fig 4C). We did not detect MenaINV signal in any of the cells expressing these markers and conclude that MenaINV is either absent or expressed at low levels in these stromal subtypes.
MenaINV expression is not restricted to cells that have undergone EMT
To characterize the identity of the cells that express MenaINV in the tumor compartment, we compared the distribution of anti-INV staining to markers of tumor cell phenotype. First, we wondered if expression of MenaINV was associated with EMT, a process that has been associated with increased metastatic potential [23]. Antibodies to E-Cadherin and vimentin, markers for epithelial and mesenchymal phenotypes respectively, were used to examine levels of MenaINV varied throughout mouse and human tumors in relation to EMT. Line scans of the signal intensities showed regions that appeared to have relatively high MenaINV and low E-cadherin signals (Fig 5A). Quantitative analysis throughout entire image fields revealed a significant, inverse correlation between relative levels of MenaINV and of E-cadherin (Fig 5B,C): MenaINV was detected in 62% and 74% of vimentin positive cells in human and mouse tumors, respectively (Fig 5D), however, vimentin was detected in only 27% and 18% of MenaINV -positive cells in human and mouse tumors, respectively. Together, these results indicate that while MenaINV proteindistribution is inversely correlated with E-Cadherin, it is observed frequently in cells lacking vimentin, a canonical marker for passage through EMT.
MenaINV expression is not enriched with cells expressing proliferation and stem cell markers
More recently, EMT has been associated with the gain of stem cell characteristics, which endow cells with the ability to metastasize and colonize more efficiently [24]. We investigated whether expression of MenaINV was associated with the proliferation or acquisition of stem cell characteristics. First, we examined the proliferation levels of MenaINV-positive cells, by staining for the proliferation marker Ki67 (Fig 6A). In both mouse and human tumors, approximately 30% of MenaINV cells were Ki67-positive. Conversely, approximately 50% of Ki67-positive cells were MenaINV-positive (Fig 6B,C). These data suggest that MenaINV expression is not restricted to highly proliferative cells. Secondly, we examined MenaINV expression relative to two known stem cell markers in mouse PyMT tumors, ALDH and CD133, whose expression has been associated with stemness (Fig 6D). Indeed, recent studies have shown that cells expressing high levels of CD133 showed higher invasive potential and drug resistance, while cells that were ALDH- and CD133-positive were highly tumorigenic [25]–[27]. As expected, we observed a positive correlation between CD133 and ALDH expression (Fig 6E); however, no significant association between cells expressing MenaINV and those expressing canonical stem cell markers. Only 15% and 23% of
MenaINV-positive cells expressed CD133 or ALDH, respectively (Fig 6F,H). Similarly, approximately 28% and 41% of CD133- and ALDH-positive cells, respectively, expressed MenaINV in PyMT tumors (Fig 6F,H). These data indicate that MenaINV is expressed in both stem and non-stem cell populations within
advanced tumors. We compared MenaINV and CD133 or ALDH staining intensity in different regions of PyMT tumors and observed no significant correlation between MenaINV signal and the levels of these stem cell markers.
MenaINV expression is high in vascularized tumor areas
Dissemination of primary tumor cells occurs primarily through the vasculature and lymphatics. We examined patterns of MenaINV expression relative to blood vessels in mouse and human tumors. In both mouse and human tumors, we found that MenaINV expression was not restricted to cells adjacent to blood vessels (Fig 7A, B). However, there was a significant correlation between MenaINV expression levels and blood vessel density in both non-metastatic and metastatic human tumors (Fig 7C). Together, these data confirm that while MenaINV expression is associated with higher blood vessel density, it is not restricted to expression in cells adjacent to the vasculature.
Blood vessel density can also affect oxygen levels within a tumor, which in turn, can drive metastatic phenotypes. Using hypoxyprobe to label hypoxic tumor areas [28], we quantified MenaINV staining intensity in PyMT-MMTV tumors relative to hypoxia (Fig 7D,E) and determined that MenaINV expression was not restricted to hypoxic areas within the tumor.
Discussion
The data presented here provide the first characterization of endogenous MenaINV protein expression in mouse breast cancer models and in human invasive ductal carcinomas. Our studies reveal that expression of MenaINV is heterogeneously distributed in tumors and that MenaINV expression can be detected in early tumors with increasing levels during early tumor progression. Our comparison of MenaINV staining to the distributions of well-established markers provides insight into the nature of the tumor cells that express MenaINV.
We developed a MenaINV isoform-specific monoclonal antibody, and demonstrated its specificity and functionality in ELISA and Western blot assays, and for immunodetection of endogenously expressed protein in human and mouse sections of FFPE tumor tissue. Our analysis provides important information on the propoerties of cells that express MenaINV, allowing us to gain further insight into the potential mechanisms by which it drives metastasis. We show that MenaINV expression is not enriched in cells with increased proliferation as identified by Ki67, or stemness, as identified by cancer stem cell markers CD133 and ALDH. Furthermore, we show that within the tumor microenvironment, MenaINV expression is absent from macrophages, endothelial cells and fibroblasts, suggesting it is likely restricted to the tumor
compartment. Finally, we show that while expression of MenaINV is high in areas of high blood vessel density, it is heterogeneous within the primary tumor and not confined to cells adjacent to blood vessels. In fact, MenaINV expression can also be detected in non- (or perhaps pre-) invasive tumor compartments with an intact basement membrane, suggesting that MenaINV is expressed early during breast cancer progression and in multiple locations. Together, these data suggest the role of MenaINV in promoting invasion and metastasis is not restricted to a role only in perivascular tumor cells at sites of intravasation, like those found in TMEM. This finding is consistent with our previous work showing that MenaINV promotes matrix degradation, paracrine signaling with macrophages, discohesive tumor morphology and increased tumor cell motility[12], [15], [30]. As recent work demonstrates that the Mena-expressing tumor cell in TMEM is relatively stable [8], it will be interesting to determine whether and how MenaINV may contribute to TMEM assembly and function.
We have yet to identify what aspects of the tumor microenvironment drive MenaINV expression or the identity of the splicing factor(s) responsable for INV inclusion. During tumor progression, EMT-associated transcription factors including Twist, Snail and Zeb1 drive a wide variety of alternative splicing that contribute to the mesenchymal phenotype and drive increased motility [29]. Here, we find that MenaINV expression in mouse and human tumors is not restricted to either epithelial or mesenchymal cells, suggesting that a full passage through EMT is not required for INV inclusion. A variety of other
microenvironmental characteristics can facilitate tumor progression and could be responsible for promoting inclusion of INV. We initially hypothesized that increases in blood vessel density or changes in oxygen availability might drive INV inclusion. However, we found that MenaINV expression is not confined to hypoxic or highly vascularized areas within tumor, suggesting that these factors alone may not be sufficient to induce MenaINV expression.
Changes in extracellular matrix composition or mechanical stimuli and secretion of a variety of soluble factors from tumor-associated stroma or the immune system also play an important role during tumor progression. We hypothesize that stiffness changes in combination with stromal factors will inclusion of the INV exon. Future work, using in part the assays described in this manuscript, will focus on how these combined stimuli might drive MenaINV expression. Once the signals that trigger MenaINV protein
accumulation are defined, it will be interesting to determine whether expression of other cancer relevant protein isoforms is regulated coordinately with MenaINV. Whether this substantial microenvironment-dependent increase in MenaINV protein arises predominately from changes in INV exon inclusion in its mRNA or involves additional levels of regulation is also under investigation
The development of the isoform specific antibody will also help advance the development of Mena isoform assessment as prognostic markers in cancer. Efforts are currently underway to determine whether analysis of MenaINV protein levels, either alone or in combination with other prognostic metrics associated with Mena, (e.g. MenaCalc [13] or TMEM [9]), provides clinically useful information. More recently, an
additional Mena isoform, MenaΔV6,has been identified in some mesenchymal-like tumor cell lines [31]. It will be interesting to compare the distributions of all Mena protein isoforms throughout tumor progression. Finally, we have shown that MenaINV expression sensitizes cells to several growth factors, whose signaling pathways are targets of clinical trials for metastatic breast cancer[32]. Monitoring expression of MenaINV in tumors might help optimise drug treatment for specific patients, as well as provide a means to monitor for acquired resistance to tyrosine kinase inhibitors.
Author contributions:
MJO designed and performed experiments, data analysis and prepared the manuscript. SKH developed and validated the INV antibody, designed and performed experiments and completed data analysis. NR performed immunostaining experiments and image analysis. MNM developed MenaINV ELISA, performed experiments and completed data analysis. FBG and DAL guided overall experimental design. JJ and JC contributed human tissue sections and interpretation of them. All authors commented on the manuscript.
References
[1] D. Hanahan and R. A. Weinberg, “Hallmarks of cancer: the next generation.,” Cell, vol. 144, no. 5, pp. 646–74, Mar. 2011.
[2] K. R. Levental, H. Yu, L. Kass, J. N. Lakins, M. Egeblad, J. T. Erler, S. F. T. Fong, K. Csiszar, A. Giaccia, W. Weninger, M. Yamauchi, D. L. Gasser, and V. M. Weaver, “Matrix crosslinking forces tumor progression by enhancing integrin signaling.,” Cell, vol. 139, no. 5, pp. 891–906, 2009. [3] P. Lu, V. M. Weaver, and Z. Werb, “The extracellular matrix: a dynamic niche in cancer
progression.,” J. Cell Biol., vol. 196, no. 4, pp. 395–406, 2012.
[4] J. Pouysségur, F. Dayan, and N. M. Mazure, “Hypoxia signalling in cancer and approaches to enforce tumour regression.,” Nature, vol. 441, no. 7092, pp. 437–443, 2006.
[5] J. A. Joyce and J. W. Pollard, “Microenvironmental regulation of metastasis.,” Nat. Rev. Cancer, vol. 9, no. 4, pp. 239–252, 2009.
[6] F. Gertler and J. Condeelis, “Metastasis: tumor cells becoming MENAcing.,” Trends Cell Biol., vol. 21, no. 2, pp. 81–90, Mar. 2011.
[7] E. T. Roussos, Y. Wang, J. B. Wyckoff, R. S. Sellers, W. Wang, J. Li, J. W. Pollard, F. B. Gertler, and J. S. Condeelis, “Mena deficiency delays tumor progression and decreases metastasis in polyoma middle-T transgenic mouse mammary tumors.,” Breast Cancer Res., vol. 12, no. 6, p. R101, Jan. 2010.
[8] A. S. Harney, E. N. Arwert, D. Entenberg, Y. Wang, P. Guo, B.-Z. Qian, M. H. Oktay, J. W. Pollard, J. G. Jones, and J. S. Condeelis, “Real-Time Imaging Reveals Local, Transient Vascular Permeability, and Tumor Cell Intravasation Stimulated by TIE2hi Macrophage-Derived VEGFA.,”
Cancer Discov., Aug. 2015.
[9] B. D. Robinson, G. L. Sica, Y.-F. Liu, T. E. Rohan, F. B. Gertler, J. S. Condeelis, and J. G. Jones, “Tumor microenvironment of metastasis in human breast carcinoma: a potential prognostic marker linked to hematogenous dissemination.,” Clin. Cancer Res., vol. 15, no. 7, pp. 2433–41, Apr. 2009. [10] T. E. Rohan, X. Xue, H.-M. Lin, T. M. D’Alfonso, P. S. Ginter, M. H. Oktay, B. D. Robinson, M.
Ginsberg, F. B. Gertler, A. G. Glass, J. a Sparano, J. S. Condeelis, and J. G. Jones, “Tumor microenvironment of metastasis and risk of distant metastasis of breast cancer.,” J. Natl. Cancer
Inst., vol. 106, no. 8, pp. 1–11, Aug. 2014.
[11] S. Goswami, U. Philippar, D. Sun, A. Patsialou, J. Avraham, W. Wang, F. Di Modugno, P. Nistico, F. B. Gertler, and J. S. Condeelis, “Identification of invasion specific splice variants of the
cytoskeletal protein Mena present in mammary tumor cells during invasion in vivo.,” Clin. Exp.
Metastasis, vol. 26, no. 2, pp. 153–9, Jan. 2009.
[12] E. T. Roussos, M. Balsamo, S. K. Alford, J. B. Wyckoff, B. Gligorijevic, Y. Wang, M. Pozzuto, R. Stobezki, S. Goswami, J. E. Segall, D. A. Lauffenburger, A. R. Bresnick, F. B. Gertler, and J. S. Condeelis, “Mena invasive (MenaINV) promotes multicellular streaming motility and
transendothelial migration in a mouse model of breast cancer.,” J. Cell Sci., vol. 124, no. Pt 13, pp. 2120–2131, 2011.
[13] S. Agarwal, F. B. Gertler, M. Balsamo, J. S. Condeelis, R. L. Camp, X. Xue, J. Lin, T. E. Rohan, and D. L. Rimm, “Quantitative assessment of invasive mena isoforms (Menacalc) as an
independent prognostic marker in breast cancer.,” Breast Cancer Res., vol. 14, no. 5, p. R124, 2012.
[14] C. L. Forse, S. Agarwal, D. Pinnaduwage, F. Gertler, J. S. Condeelis, J. Lin, X. Xue, K. Johung, A. M. Mulligan, T. E. Rohan, S. B. Bull, and I. L. Andrulis, “Menacalc, a quantitative method of metastasis assessment, as a prognostic marker for axillary node-negative breast cancer.,” BMC
Cancer, vol. 15, p. 483, Jan. 2015.
[15] U. Philippar, E. T. Roussos, M. Oser, H. Yamaguchi, H.-D. Kim, S. Giampieri, Y. Wang, S. Goswami, J. B. Wyckoff, D. A. Lauffenburger, E. Sahai, J. S. Condeelis, and F. B. Gertler, “A Mena Invasion Isoform Potentiates EGF-Induced Carcinoma Cell Invasion and Metastasis,” Dev.
Cell, vol. 15, no. 6, pp. 813–828, 2008.
[16] J. Pignatelli, S. Goswami, J. G. Jones, T. E. Rohan, E. Pieri, X. Chen, E. Adler, D. Cox, S. Maleki, A. Bresnick, F. B. Gertler, J. S. Condeelis, and M. H. Oktay, “Invasive breast carcinoma cells from patients exhibit MenaINV- and macrophage-dependent transendothelial migration.,” Sci. Signal., vol. 7, no. 353, p. ra112, Dec. 2014.
[17] E. T. Roussos, S. Goswami, M. Balsamo, Y. Wang, R. Stobezki, E. Adler, B. D. Robinson, J. G. Jones, F. B. Gertler, J. S. Condeelis, and M. H. Oktay, “Mena invasive (Mena(INV)) and Mena11a isoforms play distinct roles in breast cancer cell cohesion and association with TMEM.,” Clin. Exp.
Metastasis, vol. 28, no. 6, pp. 515–27, Aug. 2011.
[18] F. B. Gertler, K. Niebuhr, M. Reinhard, J. Wehland, and P. Soriano, “Mena, a relative of VASP and Drosophila Enabled, is implicated in the control of microfilament dynamics.,” Cell, vol. 87, no. 2, pp. 227–239, 1996.
[19] C. Lebrand, E. W. Dent, G. A. Strasser, L. M. Lanier, M. Krause, T. M. Svitkina, G. G. Borisy, and F. B. Gertler, “Critical role of Ena/VASP proteins for filopodia formation in neurons and in function downstream of netrin-1,” Neuron, vol. 42, pp. 37–49, 2004.
[20] J. E. J. E. Bear, J. J. J. J. Loureiro, I. I. Libova, R. R. Fässler, J. J. Wehland, and F. B. F. B. Gertler, “Negative regulation of fibroblast motility by Ena/VASP proteins.,” Cell, vol. 101, no. 7, pp. 717– 728, 2000.
[21] S. Goswami, U. Philippar, D. Sun, A. Patsialou, J. Avraham, W. Wang, F. Di Modugno, P. Nistico, F. B. Gertler, and J. S. Condeelis, “Identification of invasion specific splice variants of the
cytoskeletal protein Mena present in mammary tumor cells during invasion in vivo.,” Clin. Exp.
Metastasis, vol. 26, no. 2, pp. 153–159, 2009.
[22] E. Y. Lin, J. G. Jones, P. Li, L. Zhu, K. D. Whitney, W. J. Muller, and J. W. Pollard, “Progression to malignancy in the polyoma middle T oncoprotein mouse breast cancer model provides a reliable model for human diseases.,” Am. J. Pathol., vol. 163, no. 5, pp. 2113–26, Nov. 2003.
[23] S. Valastyan and R. A. Weinberg, “Tumor metastasis: Molecular insights and evolving paradigms,”
Cell, vol. 147. pp. 275–292, 2011.
[24] C. L. Chaffer, N. D. Marjanovic, T. Lee, G. Bell, C. G. Kleer, F. Reinhardt, A. C. D’Alessio, R. A. Young, and R. A. Weinberg, “Poised chromatin at the ZEB1 promoter enables breast cancer cell plasticity and enhances tumorigenicity.,” Cell, vol. 154, no. 1, pp. 61–74, Jul. 2013.
[25] F. Brugnoli, S. Grassilli, M. Piazzi, M. Palomba, E. Nika, A. Bavelloni, S. Capitani, and V. Bertagnolo, “In triple negative breast tumor cells, PLC-β2 promotes the conversion of CD133high
to CD133low phenotype and reduces the CD133-related invasiveness.,” Mol. Cancer, vol. 12, p. 165, Jan. 2013.
[26] Y.-C. Chen, Y.-W. Chen, H.-S. Hsu, L.-M. Tseng, P.-I. Huang, K.-H. Lu, D.-T. Chen, L.-K. Tai, M.-C. Yung, S.-C. Chang, H.-H. Ku, S.-H. Chiou, and W.-L. Lo, “Aldehyde dehydrogenase 1 is a putative marker for cancer stem cells in head and neck squamous cancer.,” Biochem. Biophys. Res.
Commun., vol. 385, no. 3, pp. 307–13, Jul. 2009.
[27] C. Ginestier, M. H. Hur, E. Charafe-Jauffret, F. Monville, J. Dutcher, M. Brown, J. Jacquemier, P. Viens, C. G. Kleer, S. Liu, A. Schott, D. Hayes, D. Birnbaum, M. S. Wicha, and G. Dontu, “ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome.,” Cell Stem Cell, vol. 1, no. 5, pp. 555–67, Nov. 2007.
[28] P. A. Murphy, T. N. Kim, G. Lu, A. W. Bollen, C. B. Schaffer, and R. A. Wang, “Notch4
normalization reduces blood vessel size in arteriovenous malformations.,” Sci. Transl. Med., vol. 4, no. 117, p. 117ra8, Jan. 2012.
[29] I. M. Shapiro, A. W. Cheng, N. C. Flytzanis, M. Balsamo, J. S. Condeelis, M. H. Oktay, C. B. Burge, and F. B. Gertler, “An EMT-driven alternative splicing program occurs in human breast cancer and modulates cellular phenotype.,” PLoS Genet., vol. 7, no. 8, p. e1002218, Aug. 2011. [30] E. T. Roussos, S. Goswami, M. Balsamo, Y. Wang, R. Stobezki, E. Adler, B. D. Robinson, J. G.
Jones, F. B. Gertler, J. S. Condeelis, and M. H. Oktay, “Mena invasive (Mena(INV)) and Mena11a isoforms play distinct roles in breast cancer cell cohesion and association with TMEM.,” Clin. Exp.
Metastasis, vol. 28, no. 6, pp. 515–527, 2011.
[31] F. Di Modugno, P. Iapicca, A. Boudreau, M. Mottolese, I. Terrenato, L. Perracchio, R. P. Carstens, A. Santoni, M. J. Bissell, and P. Nisticò, “Splicing program of human MENA produces a
previously undescribed isoform associated with invasive, mesenchymal-like breast tumors.,” Proc.
Natl. Acad. Sci. U. S. A., vol. 109, no. 47, pp. 19280–5, Nov. 2012.
[32] D. Zardavas, J. Baselga, and M. Piccart, “Emerging targeted agents in metastatic breast cancer.,”
Materials and Methods
Antibodies
The following antibodies were used for immunohistochemistry: CD31 (R&D Systems, AF806), Vimentin (BD, RV202), Ecadherin (CST, 24E10), panMena [19], Ki67 (CST #9037), CD133 (EBioscience, clone 13A4), ALDH (BD, Clone 44) , Iba1 (Abcam ab15690), αSMA (Sigma clone 1A4).
Production of anti-INV monoclonal antibody
Rabbit monoclonal antibodies were generated by Epitomics, INC. Animals were immunized with a peptide containing the sequence encoded by the INV exon. Clones were screened for MenaINV specificity in Western blot assays and by immunostaining of FFPE tumor sections from wild type or Mena-null mice (Fig S1).
Anti-INV ELISA
MenaINV protein levels in lysates were quantified by a custom sandwich ELISA. Anti-panMena antibody (1.8 g/mL) was coated overnight at 4°C in 96-well Nunc Maxisorb plates (Sigma). After washing with PBS + 0.5% Tween-20, assay plates were blocked at 25°C with Licor Odyssey Blocking Buffer (Licor) and lysates were added overnight at 4°C. Anti-MenaINV antibody (0.38
g/mL) was added for 2 hr at 25°C. Anti-rabbit horseradish peroxidase secondary antibody (1:4000) (Millipore) and TMB substrate (Sigma) were used for detection. Recombinant proteins that contained a 6XHIS-tagged Mena-EVH1-INV-LERER sequence or a control 6XHIS-tagged Mena-EVH1-LERER construct that lacks the 19 residue INV peptide sequence were utilized to create a standard curve via 4-parameter logistic regression in MATLAB, or act as a negative control, respectively. Relative protein concentrations were normalized to total protein content in μg.
Cell culture
All breast cancer cell lines were obtained from ATCC and cultured in DMEM+ 10% FBS (Hyclone). Cell lines were engineered to stably express 10-15 fold higher levels of Mena isoforms more than wild-type cell lines.
Mouse models
All animal experiments were approved by the MIT Division of Comparative Medicine. PyMT-MMTV mice at 12 weeks of age were injected with 10mg/kg Hypoxyprobe 1hr before sacrifice. To detect hypoxic areas, we used the Hypoxyprobe kit according to the manufacturer’s protocol [28]. We injected 60 mg/kg of Piminidazole-HCl IP 1hr before sacrificing mice. Signal was then detected by immunostaining. Dissected tumors were dissociated using lysis buffer (see below) and mortar and pestle.
Western Blotting
MDAMB231 expressing different Mena isoforms were lysed in 25mM Tris, 150mM NaCl, 10% glycerol, 1% NP 40 and 0.5M EDTA with a protease Mini-complete protease inhibitors (Roche) and a phosphatase inhibitor cocktail (PhosSTOP, Roche) at 4°C. Protein lysates were separated by SDS-PAGE, transferred to a nitrocellulose membrane, blocked with Odyssey Blocking Buffer (LiCor), incubated in primary antibody overnight at 4°C. Proteins were detected using Licor secondary antibodies.
Immunostaining
Tumors from MMTV-PyMT mice were fixed in 10% buffered formalin and embedded in paraffin. Sections from FFPE human breast cancer tumors were obtained from Dr. Joan Jones. Tissue sections (5μm thick) were deparaffinized followed by antigen retrieval using Citra Plus solution (Biogenex). After treatment with 3% H2O2, sections were blocked with serum and incubated with primary antibodies overnight at 4°C. Fluorescently labeled secondary antibodies were added at 25°C for 2 hrs. For detection of MenaINV in FFPE sections, the INV antibody was biotinylated, followed by amplification with streptavidin-horseradish
peroxidase, tyramide-biotin amplification (Perkin Elmer), and detection with a fluorescently tagged streptavidin antibody. Serial Z series image stacks were collected using a DeltaVision microscope controlled by Softworx software (GE Health) with a 40x 1.3NA plan-apo objective and deconvolved using Softworx. Images were then analyzed using ImageJ.
Image analysis
For Figure 2, images within each panel were taken with the same settings and can be compared. However, panels A, D, E cannot be directly compared for intensity readings. Tumor area was delimited using DAPI staining, and intensity of signal was measured in each field of view using ImageJ. For Figure 3, all images were acquired simultaneously and intensity can be compared within the figure. For Figure 3G, 5D, 6A-D,F,H, analysis of expression of markers was done on a per cell basis in multiple fields of view from multiple tissue samples. The number of positive cells for a specific marker was made relative to the total number of DAPI-positive cells in the field of view. For Figure 5, custom written Matlab scripts were used for image analysis of ECadherin levels. For Figure 7, blood vessel density was quantified using ImageJ, quantifying the area covered by blood vessels as marked by CD31 staining relative to the area of the field of view.
Figure legends
Figure 1: Validation of the MenaINV antibody. (A) Schematic diagram of cancer-relevant alternatively spliced Mena isoforms and in-house antibodies utilized for detection. (B) Western Blot of MDA-MB231 cells overexpressing GFP, GFP-Mena or GFP-MenaINV. MenaINV antibody only recognizes GFP-MenaINV, while the Mena antibody recognizes both isoforms. (C) Standard curve for MenaINV ELISA assay, plotting concentration of pure recombinant protein EVH1-INV-LERER versus absorbance. Protein concentrations were estimated by comparison to purified recombinant MenaINV mini-protein. (D) MenaINV protein concentration in MVD7 fibroblasts, 231-Mena and 231-231-MenaINV cultured cells, and using EVH1-LERER as a negative control, quantified by sandwich ELISA using anti-panMena for capture and anti-MenaINV for detection. (E)
Representative images of FFPE sections from Mtln3 tumors expressing Mena or GFP-MenaINV, stained with Mena (green), MenaINV (red) and DAPI (blue). Similarly, MenaINV antibody only recognizes GFP-MenaINV, while the Mena antibody recognizes both isoforms. (F) Staining for Mena and MenaINV on an FFPE section from a wild-type PyMT mouse or a PyMT mouse null for Mena. Scale bar is 30 μm.
Figure 2: MenaINV expression increases during tumor progression. A) Representative images of FFPE sections from a normal mammary fat pad tissue from an adult mouse and an advanced MMTV-PYMT tumor stained for Mena, MenaINV and DAPI. Scale bar is 30 μm. Quantification of Mena (B) and MenaINV (C) staining intensity in mammary fat pad vs. advanced tumor. (D) Representative images of FFPE sections from an MMTV-PYMT tumor stained for MenaINV, the basement member laminin and DAPI. Scale bar is 30 μm. E) Representative images of areas from MMTV-PyMT tumor sections depicting hyperplasia, adenoma and carcinoma tumor. H&E image depicts histology of area chosen for for Mena, MenaINV and DAPI staining. Scale bar is 100 μm for H&E image, and 30 μm for fluorescent images. Quantification of Mena (F) and MenaINV (G) staining intensity in different areas of PyMT tumors. Data pooled from 4 tumors, with at least 4 fields of view per sample. Each dot represents a field of view. Asterisk indicates significant difference by t-test (*p< 0.05).
Figure 3: MenaINV expression patterns in human breast cancer. Representative images of human breast tumor FFPE sections with H&E staining (A,D,G), low (B,E,H) and high (C,F,I) magnification images of immunofluorescence staining for for Mena (red) and MenaINV (green). Images are from a non-metastatic (A,B,C), DCIS (D,E,F) and metastatic tumor (G,H,I). Scale bar for A,D,G is 300 μm, for B,E,H is 100 μm and 30 μm for C,F,I. (J) Quantification of the
percentage of total cells (as counted by DAPI staining) expressing MenaINV within a 40X field. Quantification of Mena (K) and MenaINV (L) staining intensity in non-metastatic and metastatic human tumor samples. Data pooled for 3 metastatic and 3 non-metastatic samples, with at least 3 fields of view per sample. Each dot represents a field of view. Asterisk indicates significant difference by t-test (**p< 0.01).
Figure 4: MenaINV expression is restricted to the tumor compartment
Representative images of staining for MenaINV and the macrophage marker Iba1 (A,B), the fibroblast marker αSMA (C,D) and the endothelial cell marker CD31 (E,F). B,C,D show magnification of boxed area and signal intensity for both markers is quantified along the white line. Scale bar for A,C,E is 30 μm and 10 μm for B,D,F.
Figure 5: MenaINV expression and EMT markers. (A) MMV-PyMT tissue section stained for MenaINV (green) and the epithelial marker ECadherin (green). (B1-2) Intensity of MenaINV and ECadherin signal along two lines shown in panel A. (B) Mean fluorescence signal intensity
plotted for MenaINV intensity > 0.55 and E-Cadherin intensity < 0.5. (C) Mean fluorescence signal intensity plotted for E-Cadherin intensity > 0.55 and MenaINV intensity < 0.5. Raw pixel values were normalized by the range of intensities in each image. n = 5 mice, 3 image fields per tumor. (D) MMTV-PyMT tissue section stained for MenaINV (red) and vimentin (green). (D1) Black bar quantifies the fraction of vimentin-positive cells that are also MenaINV-positive, grey bar
quantifies the fraction of MenaINV-positive cells that are also vimentin-positive. Results are shown as mean +/- SEM = 2 mice, 5-7 image fields per tumor for F and G. Scale bar = 20 μm for F and G. (D2) Black bar quantifies the fraction of vimentin+ cells that are also MenaINV+ in human sections, grey bar quantifies the fraction of MenaINV-positive cells that are also vimentin+. Results are shown as mean +/- SEM, n = 2, 5-7 image fields per tumor for F and G.
Figure 6: MenaINV expression is not restricted to cancer stem cells. (A) Representative images of PyMT tumors and human breast tumors stained for MenaINV (green) and Ki67 (red). Scale bar is 30 μm (B) Quantification of the fraction of MenaINV
-positive cells that are also Ki67-positive and the fraction of Ki67-positive cells that are also MenaINV-positive in mouse PyMT tumors. Results are shown as mean +/- SEM, n = 2 mice, 5 image fields per mouse. (C) Quantification of the fraction of MenaINV-positive cells that are also Ki67-positive and the fraction of Ki67-positive cells that are also MenaINV-positive in human breast tumors from metastatic and non-metastatic patients. Results are shown as mean +/- SEM, n = 3 tumors, 5 image fields per tumor. (D) Representative images of PyMT tumors stained for MenaINV (green) and the stem cell markers ALDH (red) and CD133 (blue). (E) Positive correlation between staining intensity for CD133 and ALDH in PyMT sections. E) Quantification of the fraction of MenaINV-positive cells that are also CD133-positive and the fraction of CD133-positive cells that are also MenaINV-positive in mouse PyMT tumors. F) Correlation between MenaINV and CD133 staining intensity in PyMT tumors. G) Quantification of the fraction of MenaINV-positive cells that are also ALDH-positive and the fraction of ALDH--positive cells that are also MenaINV-positive in mouse PyMT tumors. F) Correlation between MenaINV and ALDH staining intensity in PyMT tumors. Results are shown as mean +/- SEM, n = 4 tumors, 3-5 image fields per sample.
Figure 7: MenaINV expression is high in vascularized areas
(A) MMTV-PyMT and human tissue section stained for MenaINV (green) and the endothelial marker CD31 (red). Scale bar is 30μm. (B) Representative images of human beast tumors from a metastatic and non-metastatic tumor, showing staining for MenaINV (green) and the endothelial marker CD31 (red). Scale bar is 100μm (C) Correlation between blood vessel density and MenaINV staining intensity in human breast tumors. Data pooled for 3 metastatic and 3 non-metastatic samples, with 2-3 fields of view per sample. Each dot represents a field of view. (E) Representative image from an MMTV-PyMT tumor stained for MenaINV and hypoxic areas, which were detected using the Hypoxyprobe. Scale bar is 100μm. (F) Correlation between hypoxia (as measured by intensity of the Hypoxyprobe staining) and MenaINV staining intensity in PyMT-MMTV tumors. Data pooled from 2 tumors, with over 40 fields of view analyzed. Each dot represents a field of view.
Figure S1: Table with characteristics of human tumors
Table summarizing clinical features of human breast cancer tumors used for
immunohistochemical analyses: tumor size, ER, PR or Her2 status, lymph node (LN) positivity, and site of metastasis.
